GlassScriptPhysician profile
Sarah Adkins
NPI 1265039044
$3,375.36
in general payments reported to CMS, 2019-2025
36 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $469 · 2023: $377 · 2024: $1,111 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,756.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $618.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $451.37 | 2024-2025 | Freestyle Libre, Freestyle Libre 3, Cardiomems |
| Gilead Sciences, INC. | $304.23 | 2024-2025 | Descovy, Yeztugo |
| Lilly USA, LLC | $258.56 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $216.06 | 2022-2025 | Airsupra, Farxiga |
| Amgen INC. | $158.40 | 2021-2025 | Repatha, Repatha, Otezla |
| Viiv Healthcare Company | $144.72 | 2024-2025 | Apretude |
| Novartis Pharmaceuticals Corporation | $128.91 | 2022-2025 | |
| Dexcom, INC. | $103.01 | 2022-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $87.96 | 2022-2025 | |
| Astellas Pharma US INC | $83.86 | 2024-2025 | Veozah |
| Abbvie INC. | $82.08 | 2022-2025 | |
| Glaxosmithkline, LLC. | $73.58 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Jazz Pharmaceuticals INC. | $64.01 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $60.74 | 2024-2025 | Gemtesa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $59.73 | 2022 | |
| Janssen Pharmaceuticals, INC | $45.53 | 2023-2024 | Xarelto |
| Inspire Medical Systems, INC. | $43.96 | 2024 | Inspire |
| Genentech USA, INC. | $36.30 | 2021 | |
| Averitas Pharma INC. | $34.77 | 2024 | Qutenza |
| Tactile Systems Technology INC | $34.73 | 2022 | |
| Corcept Therapeutics | $26.21 | 2024 | Korlym |
| Horizon Therapeutics Plc | $25.23 | 2022 | |
| Esperion Therapeutics, INC. | $21.63 | 2021 | |
| Mannkind Corporation | $21.19 | 2024 | |
| Bioventus LLC | $21.18 | 2025 | Gelsyn-3 |
| Merck Sharp & Dohme LLC | $21.10 | 2024 | Verquvo |
| Boston Scientific Corporation | $20.73 | 2025 | Cds - Mct/Cem Monitoring |
| Currax Pharmaceuticals LLC | $18.94 | 2025 | Contrave |
| Amarin Pharma, INC. | $18.42 | 2022 | |
| Pfizer INC. | $18.11 | 2025 | |
| Idorsia Pharmaceuticals US INC | $16.18 | 2022 | |
| Daiichi Sankyo INC. | $15.58 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.90 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.80 | 2025 | Voquezna |
| Redhill Biopharma INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.